Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06069869 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Multiple Micronutrient Supplementation (MMS) Iron Dose Acceptability Crossover Trial

Study acronym: MID-ACT
StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated May 8, 2026 (before its estimated June 24, 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv10
  2. Primary completion pushed from Jan 23, 2026 to Jun 24, 2026
    • Study completion pushed from Apr 24, 2026 to Jun 24, 2026
    v9
  3. Trial status: Recruiting to Active, Not Recruitingv8 Show 4 more changesShow less
    • Primary completion date changed from estimate of Mar 2026 to Jan 23, 2026
    • Study completion date: Mar 2026 to Apr 24, 2026
    • Secondary endpoints: details revised at 2 of 5 entries
    • Site details revised
  4. Trial status: Not Yet Recruiting to Recruitingv7 Show 4 more changesShow less
    • Study sites: 0 to 1
    • Primary and study completion dates: Dec 2025 to Mar 2026
    • Start date changed from estimate of Aug 2025 to Sep 26, 2025
    • Secondary endpoints: 3 to 5
  5. Start date: Mar 2025 to Aug 2025
    • Eligibility criteria expanded, about 14 words
    v6
Show 4 earlier versionsHide 4 earlier versions
  1. Start date: Nov 2024 to Mar 2025v5
  2. Re-verified, no change to tracked fieldsv4
  3. Start date: Sep 2025 to Nov 2024
    • Secondary endpoints: 4 to 3
    v3
  4. Primary endpoints: 9 to 1
    • Eligibility criteria expanded, about 7 words
    • Secondary endpoints expanded, about 14 words
    • Study title shortened, about 7 words
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is an individually randomized cross-over trial to assess acceptability, preference, and perceived side effects of MMS formulations with 30 mg, 45 mg and 60 mg of iron.
Trial Details
NCT Number NCT06069869
Lead Sponsor George Washington University
Collaborators: Ifakara Health Institute, Harvard School of Public Health (HSPH), Muhimbili University of Health and Allied Sciences, Africa Academy for Public Health, Columbia University
Conditions
(from sponsor)		 Pregnancy Related
Enrollment 156 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov